Combination therapy with interferon-α and ribavirin for hepatitis C: Practical treatment issues

BioDrugs

Volumn 15, Issue 4, 2001, Pages 225-238

  Collier, J ^a   Chapman, R ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMANTADINE; AMINOTRANSFERASE; MACROGOL; RIBAVIRIN; VIRUS RNA;

ALCOHOL CONSUMPTION; ALOPECIA; ANEMIA; ANOREXIA; CHILDHOOD DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG FORMULATION; DRUG RESPONSE; DYSPNEA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER BIOPSY; LIVER CIRRHOSIS; MENTAL DISEASE; MONITORING; NAUSEA; NEUROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RASH; RECURRENT INFECTION; RESPIRATORY TRACT DISEASE; REVIEW; THYROID DISEASE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRUS LOAD; VIRUS TYPING;

EID: 0034796575     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115040-00003     Document Type: Review

References (47)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt
3. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
4. Natural history of liver fibrosis progression in patients with chronic hepatitis C
5. Viral heterogeneity of the hepatitis C virus
6. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
7. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
8. Interferon therapy reduces the risk of hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan
9. Randomised trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
10. Treatment of hepatitis C virus-related cirrhosis: A randomised, controlled trial of interferon alfa-2b versus no treatment
11. Hepatitis C virus infection: Quality of life and side-effects of treatment
12. Reduction of health related quality of life in chronic hepatitis C and improvement with interferon therapy
13. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C
14. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
15. The significance of baseline serum alanine aminotransferase on pre-treatment disease characteristics and response to antiviral therapy in chronic hepatitis C
16. Consensus statement
17. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
18. Peginterferon alfa-2-a in patients with chronic hepatitis C and cirrhosis
19. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
20. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapse after, interferon alpha therapy: A randomised trial
21. A randomised trial of ribavirin and interferon-alpha versus interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment
22. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials
23. Is an 'à la carte' combination of interferon alpha-2b plus ribavirin regime possible for the first line treatment in patients with chronic hepatitis C?
24. Standardization of hepatitis C virus-RNA quantification: Advances and unfinished business
25. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond
26. Neurovisual impairment: A frequent complication of alpha-interferon treatment for chronic viral hepatitis
27. Interferon-alpha induced thyroid dysfunction: Three clinical presentations and a review of the literature
28. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
29. Clinical implications of hepatitis C viral kinetics
30. Peginterferon alfa-2-a in patients with chronic hepatitis C
31. Peginterferon alfa-2-b plus ribavirin compared to interferon alfa-2-b plus ribavirin for the treatment of chronic hepatitis C: A 24 week treatment analysis of a multicentre, multinational phase III randomised controlled trial
32. Cost effectiveness of interferon alpha 2b combined with ribavirin for the treatment of chronic hepatitis C
33. The roles of amantidine, rimantadine, ursodeoxycholic acid and NSAIDs alone or in combination with alpha interferon in the treatment of chronic hepatitis C
34. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantidine as initial therapy for chronic hepatitis C
35. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
36. Interferon as treatment for acute hepatitis C. A meta-analysis
37. Interferon therapy for acute hepatitis C viral infection - A review by meta-analysis
38. Interferon alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy
39. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission
40. The role for liver biopsy in haemophiliacs infected with the hepatitis C virus
41. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report
42. Efficacy and safety of combination therapy with interferon alpha 2b and ribavirin for chronic hepatitis C in HIV infected patients
43. Combination therapy of interferon alpha-2b and ribavirin for recurrent hepatitis C after liver transplantation
44. Therapy of chronic hepatitis C after liver transplantation: Multicenter Italian experience
45. Combination of interferon alfa 2-b plus ribavirin for recurrent HCV infection after liver transplantation: A randomised controlled study
46. Pilot study of the combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation
47. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination